항생제 내성 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Antibiotic Resistance Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 6,919,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,105,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,768,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

세계 항생제 내성 시장 규모는 2025년에 118억 달러로 2025-2032년 예측 기간 동안 5.4%의 CAGR로 확대되어 2032년에는 170억 8,000만 달러에 달할 것으로 예상됩니다.

항생제 내성은 항생제 남용과 오남용으로 인한 세계 보건 위기의 확대이며, 약제 내성균의 출현으로 이어지고 있습니다. 이 시장에는 진단약, 신규 항생제 개발, 대체 요법, 내성균 대응을 위한 항균제 스튜어드십 프로그램 등이 포함됩니다. 혁신적인 항생제, 신속 진단 검사, 박테리오파지 요법 및 항균 펩타이드와 같은 비 전통적 치료법에 대한 수요가 시장 성장을 주도하고 있습니다. 항생제 내성 시장은 제약회사, 생명공학 기업, 의료 서비스 제공자, 연구기관에 서비스를 제공하여 다제내성 감염에 대한 효과적인 해결책에 대한 긴급한 요구를 충족시키고 있습니다.

세계 항생제 내성 시장은 약제 내성 감염의 확산, 병원내 감염으로 인한 부담 증가, 항균제 스튜어드십 프로그램의 중요성 증가 등 몇 가지 주요 요인에 의해 주도되고 있습니다. 내성 병원균의 조기 발견을 위한 신속 진단 도구의 개발은 시장 개척을 가속화하고 있습니다. 항생제 연구에 대한 정부의 노력과 자금 지원, 신속 승인 및 시장 독점권과 같은 규제 혜택은 시장 성장을 더욱 촉진하고 있습니다. 또한, AI를 활용한 신약 개발 및 미생물 기반 치료법과 같은 바이오테크놀러지의 발전은 내성균에 효과적으로 대응할 수 있는 새로운 기회를 제공하고 있습니다.

항생제 내성 시장은 신약 개발, 맞춤형 의료 접근법, 디지털 헬스 기술 통합으로 인해 큰 성장 기회를 맞이하고 있습니다. 병용요법, 병원체 동정을 위한 차세대 염기서열 분석(NGS), 항균제 내성 관리를 위한 AI 기반 예측 분석에 대한 수요가 증가하면서 시장 전망이 재편되고 있습니다. 책임감 있는 항균제 사용을 장려하는 공중보건 노력과 항균제 혁신을 지원하는 세계 자금 지원 프로그램은 이해관계자들에게 더 많은 기회를 창출하고 있습니다. 의료 기관, 연구 기관, 제약사 간의 국제 협력 강화는 시장 확대를 가속화하고 항생제 내성의 세계 위협에 대응하는 데 있어 매우 중요합니다.

세계의 항생제 내성 시장에 대해 조사했으며, 약제 종류별, 병원체별, 질병별, 작용기전별, 유통 채널별, 지역별 동향, 시장 진입 기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
• 거시경제 요인
• COVID-19의 영향 분석
• 예측요인 - 관련성과 영향

제3장 부가가치 인사이트

제4장 세계의 항생제 내성 시장 전망

• 주요 하이라이트
• 시장 규모(10억 달러) 분석과 예측
• 세계의 항생제 내성 시장 전망 : 약물 종류별
• 세계의 항생제 내성 시장 전망 : 병원체별
• 세계의 항생제 내성 시장 전망 : 질환별
• 세계의 항생제 내성 시장 전망 : 작용기전별
• 세계의 항생제 내성 시장 전망 : 유통 채널별

제5장 세계의 항생제 내성 시장 전망 : 지역별

• 주요 하이라이트
• 과거 시장 규모(10억 달러) 분석, 지역별, 2019-2024년
• 현재 시장 규모(10억 달러) 분석과 예측, 지역별, 2025-2032년
• 시장 매력 분석 : 지역별

제6장 북미의 항생제 내성 시장 전망

제7장 유럽의 항생제 내성 시장 전망

제8장 동아시아의 항생제 내성 시장 전망

제9장 남아시아 및 오세아니아의 항생제 내성 시장 전망

제10장 라틴아메리카의 항생제 내성 시장 전망

제11장 중동 및 아프리카의 항생제 내성 시장 전망

제12장 경쟁 구도

• 시장 점유율 분석, 2025년
• 시장 구조
• 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
  • Thermo Fisher Scientific, Inc.
  • Merck KgaA
  • Bio-Rad Laboratories, Inc.
  • Takara Bio, Inc.
  • QIAGEN NV
  • Pall Corporation
  • Eppendorf Corporate
  • Tarsons Products PVT. LTD.
  • Applied Biological Materials Inc.
  • Greiner AG
  • Brooks Life Sciences
  • Corning Incorporated
  • Cytiva
  • PerkinElmer

제13장 부록

ksm

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for antibiotic resistance. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global antibiotic resistance market from 2025 to 2032.

Key Insights:

• Antibiotic Resistance Market Size (2025E): US$ 11.8 Bn
• Projected Market Value (2032F): US$ 17.08 Bn
• Global Market Growth Rate (CAGR 2025 to 2032):5.4%

Antibiotic Resistance Market - Report Scope:

Antibiotic resistance is a growing global health crisis caused by the overuse and misuse of antibiotics, leading to the emergence of drug-resistant bacteria. This market encompasses diagnostics, novel antibiotic development, alternative therapies, and antimicrobial stewardship programs aimed at combating resistance. The demand for innovative antibiotics, rapid diagnostic tests, and non-traditional treatments, such as bacteriophage therapy and antimicrobial peptides, is driving market growth. The antibiotic resistance market serves pharmaceutical companies, biotechnology firms, healthcare providers, and research institutions, addressing the urgent need for effective solutions against multidrug-resistant infections.

Market Growth Drivers:

The global antibiotic resistance market is propelled by several key factors, including the rising prevalence of drug-resistant infections, the increasing burden of hospital-acquired infections, and the growing emphasis on antimicrobial stewardship programs. The development of rapid diagnostic tools for early detection of resistant pathogens is accelerating market adoption. Government initiatives and funding for antibiotic research, along with regulatory incentives such as fast-track approvals and market exclusivity, further boost market growth. Additionally, advancements in biotechnology, including the use of AI-driven drug discovery and microbiome-based therapies, present new opportunities for tackling resistance effectively.

Market Restraints:

Despite promising growth prospects, the antibiotic resistance market faces challenges related to high research and development costs, stringent regulatory requirements, and limited return on investment for new antibiotic development. The slow adoption of alternative therapies and the lack of awareness regarding antimicrobial resistance in low- and middle-income countries hinder market expansion. Moreover, the reluctance of pharmaceutical companies to invest in antibiotic R&D due to lower profitability compared to chronic disease drugs poses a challenge to market growth. Addressing these challenges requires global collaboration, financial incentives, and increased public-private partnerships to support antibiotic innovation.

Market Opportunities:

The antibiotic resistance market presents significant growth opportunities driven by novel drug development, personalized medicine approaches, and the integration of digital health technologies. The rising demand for combination therapies, next-generation sequencing (NGS) for pathogen identification, and AI-driven predictive analytics for antimicrobial resistance management are reshaping the market landscape. Public health initiatives promoting responsible antibiotic use and global funding programs supporting antimicrobial innovation create additional opportunities for stakeholders. Strengthening international collaboration between healthcare organizations, research institutes, and pharmaceutical companies will be crucial in accelerating market expansion and combating the global threat of antibiotic resistance.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the antibiotic resistance market globally?
• Which product segments are leading market adoption, and what role do novel antibiotics and alternative therapies play?
• How are technological advancements reshaping the competitive landscape of the antibiotic resistance market?
• Who are the key players contributing to the market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global antibiotic resistance market?

Competitive Intelligence and Business Strategy:

Leading players in the global antibiotic resistance market, including Pfizer Inc., Merck & Co., GlaxoSmithKline plc, and Paratek Pharmaceuticals, are focusing on innovation, strategic partnerships, and regulatory approvals to gain a competitive edge. These companies are investing in research and development for next-generation antibiotics, bacteriophage therapy, and precision medicine-based antimicrobial solutions. Collaborations with government agencies, non-profit organizations, and biotech startups facilitate market access and accelerate the development of novel treatments. Moreover, emphasis on clinical trials, antimicrobial stewardship programs, and public awareness campaigns fosters market growth and strengthens global efforts to combat antibiotic resistance.

Key Companies Profiled:

• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Paratek Pharmaceuticals, Inc.
• Entasis Therapeutics
• Melinta Therapeutics, Inc.
• Tetraphase Pharmaceuticals, Inc.
• Achaogen, Inc.
• Nabriva Therapeutics plc
• Basilea Pharmaceutica Ltd.

Antibiotic Resistance Industry Segmentation

By Drug Class

• Beta Lactam Antibiotic
• Tetracyclines
• Lipoglycopeptides
• Combination Therapies
• Cephalosporins
• Oxazolidinones

By Pathogen

• Staphylococcus aureus
• Streptococcus pneumonia
• Vancomycin- resistant Enterococcus
• Neisseria gonorrhoeae
• Pseudomonas aeruginosa
• Escherichia coli
• Mycobacterium tuberculosis
• Acinetobacter
• Clostridium difficile

By Disease

• Community Acquired Bacterial Pneumonia (CABP)
• Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
• Complicated Urinary Tract Infections (CUTI)
• Complicated Intra- Abdominal Infections (CIAI)
• Blood Stream Infections (BSI)
• Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
• Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

By Mechanism of Action

• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Antibiotic Resistance Market Snapshot, 2025 and 2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Disease Epidemiology
• 3.3. Pipeline Analysis
• 3.4. Product Adoption Analysis
• 3.5. Value Chain Analysis
• 3.6. Key Promotional Strategies by Manufacturers
• 3.7. PESTLE Analysis
• 3.8. Porter's Five Force Analysis

4. Global Antibiotic Resistance Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn ) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn ) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn ) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn ) Analysis and Forecast, 2025-2032
• 4.3. Global Antibiotic Resistance Market Outlook: Drug Class
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn ) Analysis, By Drug Class, 2019-2024
  • 4.3.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
    • 4.3.3.1. Beta Lactam Antibiotic
    • 4.3.3.2. Tetracyclines
    • 4.3.3.3. Lipoglycopeptides
    • 4.3.3.4. Combination Therapies
    • 4.3.3.5. Cephalosporins
    • 4.3.3.6. Oxazolidinones
    • 4.3.3.7. Others
  • 4.3.4. Market Attractiveness Analysis: Drug Class
• 4.4. Global Antibiotic Resistance Market Outlook: Pathogen
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn ) Analysis, By Pathogen, 2019-2024
  • 4.4.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
    • 4.4.3.1. Staphylococcus aureus
    • 4.4.3.2. Streptococcus pneumonia
    • 4.4.3.3. Vancomycin- resistant Enterococcus
    • 4.4.3.4. Neisseria gonorrhoeae
    • 4.4.3.5. Pseudomonas aeruginosa
    • 4.4.3.6. Escherichia coli
    • 4.4.3.7. Mycobacterium tuberculosis
    • 4.4.3.8. Acinetobacter
    • 4.4.3.9. Clostridium difficile
    • 4.4.3.10. Others
  • 4.4.4. Market Attractiveness Analysis: Pathogen
• 4.5. Global Antibiotic Resistance Market Outlook: Disease
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn ) Analysis, By Disease, 2019-2024
  • 4.5.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
    • 4.5.3.1. Community Acquired Bacterial Pneumonia (CABP)
    • 4.5.3.2. Hopitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
    • 4.5.3.3. Complicated Urinary Tract Infections (CUTI)
    • 4.5.3.4. Complicated Intra- Abdominal Infections (CIAI)
    • 4.5.3.5. Blood Stream Infections (BSI)
    • 4.5.3.6. Abdominal Infection and Diarohhea (Clostridium difficile infections (CDI) & Shigella)
    • 4.5.3.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    • 4.5.3.8. Others
  • 4.5.4. Market Attractiveness Analysis: Disease
• 4.6. Global Antibiotic Resistance Market Outlook: Mechanism of Action
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Bn ) Analysis, By Mechanism of Action, 2019-2024
  • 4.6.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
    • 4.6.3.1. Cell Wall Synthesis Inhibitors
    • 4.6.3.2. Protein Synthesis Inhibitors
    • 4.6.3.3. DNA Synthesis Inhibitors
    • 4.6.3.4. RNA Synthesis Inhibitors
    • 4.6.3.5. Others
  • 4.6.4. Market Attractiveness Analysis: Mechanism of Action
• 4.7. Global Antibiotic Resistance Market Outlook: Distribution Channel
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn ) Analysis, By Distribution Channel, 2019-2024
  • 4.7.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 4.7.3.1. Hospitals Pharmacies
    • 4.7.3.2. Retail Pharmacies
    • 4.7.3.3. Online Pharmacies
  • 4.7.4. Market Attractiveness Analysis: Distribution Channel

5. Global Antibiotic Resistance Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn ) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Antibiotic Resistance Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Drug Class
  • 6.2.3. By Pathogen
  • 6.2.4. By Disease
  • 6.2.5. By Mechanism of Action
  • 6.2.6. By Distribution Channel
• 6.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
  • 6.4.1. Beta Lactam Antibiotic
  • 6.4.2. Tetracyclines
  • 6.4.3. Lipoglycopeptides
  • 6.4.4. Combination Therapies
  • 6.4.5. Cephalosporins
  • 6.4.6. Oxazolidinones
  • 6.4.7. Others
• 6.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
  • 6.5.1. Staphylococcus aureus
  • 6.5.2. Streptococcus pneumonia
  • 6.5.3. Vancomycin- resistant Enterococcus
  • 6.5.4. Neisseria gonorrhoeae
  • 6.5.5. Pseudomonas aeruginosa
  • 6.5.6. Escherichia coli
  • 6.5.7. Mycobacterium tuberculosis
  • 6.5.8. Acinetobacter
  • 6.5.9. Clostridium difficile
  • 6.5.10. Others
• 6.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
  • 6.6.1. Community Acquired Bacterial Pneumonia (CABP)
  • 6.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  • 6.6.3. Complicated Urinary Tract Infections (CUTI)
  • 6.6.4. Complicated Intra- Abdominal Infections (CIAI)
  • 6.6.5. Blood Stream Infections (BSI)
  • 6.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
  • 6.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • 6.6.8. Others
• 6.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
  • 6.7.1. Cell Wall Synthesis Inhibitors
  • 6.7.2. Protein Synthesis Inhibitors
  • 6.7.3. DNA Synthesis Inhibitors
  • 6.7.4. RNA Synthesis Inhibitors
  • 6.7.5. Others
• 6.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 6.8.1. Hospitals Pharmacies
  • 6.8.2. Retail Pharmacies
  • 6.8.3. Online Pharmacies
• 6.9. Market Attractiveness Analysis

7. Europe Antibiotic Resistance Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Drug Class
  • 7.2.3. By Pathogen
  • 7.2.4. By Disease
  • 7.2.5. By Mechanism of Action
  • 7.2.6. By Distribution Channel
• 7.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
  • 7.4.1. Beta Lactam Antibiotic
  • 7.4.2. Tetracyclines
  • 7.4.3. Lipoglycopeptides
  • 7.4.4. Combination Therapies
  • 7.4.5. Cephalosporins
  • 7.4.6. Oxazolidinones
  • 7.4.7. Others
• 7.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
  • 7.5.1. Staphylococcus aureus
  • 7.5.2. Streptococcus pneumonia
  • 7.5.3. Vancomycin- resistant Enterococcus
  • 7.5.4. Neisseria gonorrhoeae
  • 7.5.5. Pseudomonas aeruginosa
  • 7.5.6. Escherichia coli
  • 7.5.7. Mycobacterium tuberculosis
  • 7.5.8. Acinetobacter
  • 7.5.9. Clostridium difficile
  • 7.5.10. Others
• 7.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
  • 7.6.1. Community Acquired Bacterial Pneumonia (CABP)
  • 7.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  • 7.6.3. Complicated Urinary Tract Infections (CUTI)
  • 7.6.4. Complicated Intra- Abdominal Infections (CIAI)
  • 7.6.5. Blood Stream Infections (BSI)
  • 7.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
  • 7.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • 7.6.8. Others
• 7.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
  • 7.7.1. Cell Wall Synthesis Inhibitors
  • 7.7.2. Protein Synthesis Inhibitors
  • 7.7.3. DNA Synthesis Inhibitors
  • 7.7.4. RNA Synthesis Inhibitors
  • 7.7.5. Others
• 7.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 7.8.1. Hospitals Pharmacies
  • 7.8.2. Retail Pharmacies
  • 7.8.3. Online Pharmacies
• 7.9. Market Attractiveness Analysis

8. East Asia Antibiotic Resistance Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Drug Class
  • 8.2.3. By Pathogen
  • 8.2.4. By Disease
  • 8.2.5. By Mechanism of Action
  • 8.2.6. By Distribution Channel
• 8.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
  • 8.4.1. Beta Lactam Antibiotic
  • 8.4.2. Tetracyclines
  • 8.4.3. Lipoglycopeptides
  • 8.4.4. Combination Therapies
  • 8.4.5. Cephalosporins
  • 8.4.6. Oxazolidinones
  • 8.4.7. Others
• 8.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
  • 8.5.1. Staphylococcus aureus
  • 8.5.2. Streptococcus pneumonia
  • 8.5.3. Vancomycin- resistant Enterococcus
  • 8.5.4. Neisseria gonorrhoeae
  • 8.5.5. Pseudomonas aeruginosa
  • 8.5.6. Escherichia coli
  • 8.5.7. Mycobacterium tuberculosis
  • 8.5.8. Acinetobacter
  • 8.5.9. Clostridium difficile
  • 8.5.10. Others
• 8.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
  • 8.6.1. Community Acquired Bacterial Pneumonia (CABP)
  • 8.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  • 8.6.3. Complicated Urinary Tract Infections (CUTI)
  • 8.6.4. Complicated Intra- Abdominal Infections (CIAI)
  • 8.6.5. Blood Stream Infections (BSI)
  • 8.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
  • 8.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • 8.6.8. Others
• 8.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
  • 8.7.1. Cell Wall Synthesis Inhibitors
  • 8.7.2. Protein Synthesis Inhibitors
  • 8.7.3. DNA Synthesis Inhibitors
  • 8.7.4. RNA Synthesis Inhibitors
  • 8.7.5. Others
• 8.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 8.8.1. Hospitals Pharmacies
  • 8.8.2. Retail Pharmacies
  • 8.8.3. Online Pharmacies
• 8.9. Market Attractiveness Analysis

9. South Asia & Oceania Antibiotic Resistance Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Drug Class
  • 9.2.3. By Pathogen
  • 9.2.4. By Disease
  • 9.2.5. By Mechanism of Action
  • 9.2.6. By Distribution Channel
• 9.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
  • 9.4.1. Beta Lactam Antibiotic
  • 9.4.2. Tetracyclines
  • 9.4.3. Lipoglycopeptides
  • 9.4.4. Combination Therapies
  • 9.4.5. Cephalosporins
  • 9.4.6. Oxazolidinones
  • 9.4.7. Others
• 9.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
  • 9.5.1. Staphylococcus aureus
  • 9.5.2. Streptococcus pneumonia
  • 9.5.3. Vancomycin- resistant Enterococcus
  • 9.5.4. Neisseria gonorrhoeae
  • 9.5.5. Pseudomonas aeruginosa
  • 9.5.6. Escherichia coli
  • 9.5.7. Mycobacterium tuberculosis
  • 9.5.8. Acinetobacter
  • 9.5.9. Clostridium difficile
  • 9.5.10. Others
• 9.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
  • 9.6.1. Community Acquired Bacterial Pneumonia (CABP)
  • 9.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  • 9.6.3. Complicated Urinary Tract Infections (CUTI)
  • 9.6.4. Complicated Intra- Abdominal Infections (CIAI)
  • 9.6.5. Blood Stream Infections (BSI)
  • 9.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
  • 9.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • 9.6.8. Others
• 9.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
  • 9.7.1. Cell Wall Synthesis Inhibitors
  • 9.7.2. Protein Synthesis Inhibitors
  • 9.7.3. DNA Synthesis Inhibitors
  • 9.7.4. RNA Synthesis Inhibitors
  • 9.7.5. Others
• 9.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 9.8.1. Hospitals Pharmacies
  • 9.8.2. Retail Pharmacies
  • 9.8.3. Online Pharmacies
• 9.9. Market Attractiveness Analysis

10. Latin America Antibiotic Resistance Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Drug Class
  • 10.2.3. By Pathogen
  • 10.2.4. By Disease
  • 10.2.5. By Mechanism of Action
  • 10.2.6. By Distribution Channel
• 10.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
  • 10.4.1. Beta Lactam Antibiotic
  • 10.4.2. Tetracyclines
  • 10.4.3. Lipoglycopeptides
  • 10.4.4. Combination Therapies
  • 10.4.5. Cephalosporins
  • 10.4.6. Oxazolidinones
  • 10.4.7. Others
• 10.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
  • 10.5.1. Staphylococcus aureus
  • 10.5.2. Streptococcus pneumonia
  • 10.5.3. Vancomycin- resistant Enterococcus
  • 10.5.4. Neisseria gonorrhoeae
  • 10.5.5. Pseudomonas aeruginosa
  • 10.5.6. Escherichia coli
  • 10.5.7. Mycobacterium tuberculosis
  • 10.5.8. Acinetobacter
  • 10.5.9. Clostridium difficile
  • 10.5.10. Others
• 10.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
  • 10.6.1. Community Acquired Bacterial Pneumonia (CABP)
  • 10.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  • 10.6.3. Complicated Urinary Tract Infections (CUTI)
  • 10.6.4. Complicated Intra- Abdominal Infections (CIAI)
  • 10.6.5. Blood Stream Infections (BSI)
  • 10.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
  • 10.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • 10.6.8. Others
• 10.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
  • 10.7.1. Cell Wall Synthesis Inhibitors
  • 10.7.2. Protein Synthesis Inhibitors
  • 10.7.3. DNA Synthesis Inhibitors
  • 10.7.4. RNA Synthesis Inhibitors
  • 10.7.5. Others
• 10.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 10.8.1. Hospitals Pharmacies
  • 10.8.2. Retail Pharmacies
  • 10.8.3. Online Pharmacies
• 10.9. Market Attractiveness Analysis

11. Middle East & Africa Antibiotic Resistance Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Drug Class
  • 11.2.3. By Pathogen
  • 11.2.4. By Disease
  • 11.2.5. By Mechanism of Action
  • 11.2.6. By Distribution Channel
• 11.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
  • 11.4.1. Beta Lactam Antibiotic
  • 11.4.2. Tetracyclines
  • 11.4.3. Lipoglycopeptides
  • 11.4.4. Combination Therapies
  • 11.4.5. Cephalosporins
  • 11.4.6. Oxazolidinones
  • 11.4.7. Others
• 11.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
  • 11.5.1. Staphylococcus aureus
  • 11.5.2. Streptococcus pneumonia
  • 11.5.3. Vancomycin- resistant Enterococcus
  • 11.5.4. Neisseria gonorrhoeae
  • 11.5.5. Pseudomonas aeruginosa
  • 11.5.6. Escherichia coli
  • 11.5.7. Mycobacterium tuberculosis
  • 11.5.8. Acinetobacter
  • 11.5.9. Clostridium difficile
  • 11.5.10. Others
• 11.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
  • 11.6.1. Community Acquired Bacterial Pneumonia (CABP)
  • 11.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  • 11.6.3. Complicated Urinary Tract Infections (CUTI)
  • 11.6.4. Complicated Intra- Abdominal Infections (CIAI)
  • 11.6.5. Blood Stream Infections (BSI)
  • 11.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
  • 11.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • 11.6.8. Others
• 11.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
  • 11.7.1. Cell Wall Synthesis Inhibitors
  • 11.7.2. Protein Synthesis Inhibitors
  • 11.7.3. DNA Synthesis Inhibitors
  • 11.7.4. RNA Synthesis Inhibitors
  • 11.7.5. Others
• 11.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 11.8.1. Hospitals Pharmacies
  • 11.8.2. Retail Pharmacies
  • 11.8.3. Online Pharmacies
• 11.9. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Thermo Fisher Scientific, Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Merck KgaA
  • 12.3.3. Bio-Rad Laboratories, Inc.
  • 12.3.4. Takara Bio, Inc.
  • 12.3.5. QIAGEN N.V.
  • 12.3.6. Pall Corporation
  • 12.3.7. Eppendorf Corporate
  • 12.3.8. Tarsons Products PVT. LTD.
  • 12.3.9. Applied Biological Materials Inc.
  • 12.3.10. Greiner AG
  • 12.3.11. Brooks Life Sciences
  • 12.3.12. Corning Incorporated
  • 12.3.13. Cytiva
  • 12.3.14. PerkinElmer

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료